Curex vs Lttl
Two GLP-1 desks, one scoreboard. We put Curex and Lttl head-to-head on the published Brief Score — the same six factors, scored the same way.
Curex
FDA warning letter, September 2025 — issued to Curex. See the FDA's warning letter database.
The verdict
Curex takes this head-to-head.
Curex scores 86 to 68 on our six-factor Brief Score — Identical $199 pricing on both molecules, an oral route, LegitScript-certified and nationwide.
That doesn't make Lttl a bad call — it's best for readers who want the whole price matrix in front of them before they answer a single question, and who will check which term a headline figure is attached to before treating it as a monthly bill. Weigh the six factors below against your own priorities before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| Curex | Lttl | |
|---|---|---|
| Brief Score | 86/100 (B) | 68/100 (C) |
| Semaglutide | $199/mo | $199/mo (month-to-month, all doses, compounded; prepay tiers lower) |
| Tirzepatide | $199/mo | $279/mo (month-to-month, all doses, compounded; prepay tiers lower) |
| Coverage | All 50 states | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Yes | Yes |
| On the tracker | Stableprice stable | Stableprice stable |
Curex: Flat $199 on both molecules; LegitScript-certified and nationwide.
Lttl: Second reading. We filed $199/mo semaglutide and $279/mo tirzepatide on 1 August and re-read the /plans matrix on 7 August 2026: both month-to-month rates are unchanged, as are all four commitment rungs behind them. The "$129/mo" the homepage advertises is the twelve-month prepay rate, and it has not moved either.
● Not sold on either?
CoreAge Rx tops the whole ranking at 94/100.
The steadiest desk in the ranking: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.